Objective: To compare the cost-effectiveness of selective laser photocoagulation (SLP) with serial amniodrainage (AD) in the treatment of twin-to-twin transfusion syndrome (TTTS).
Introduction
Approximately 20% of all twin pregnancies are monochorionic. Twin-to-twin transfusion syndrome (TTTS) affects 15% of all monochorionic twin gestations and may result in a 90% perinatal mortality rate if untreated. 1 Moreover, among those that do survive, the risk of long-term disability in the untreated population ranges from 15 to 50%. The signficant health consequences associated with this condition make clear the importance of determining the optimal treatment strategy. To this point in time, the most common therapeutic modalities for TTTS are serial amniodrainage (AD) and selective laser photocoagulation (SLP) of placental anastomoses.
A recent European trial has suggested that SLP is a more effective treatment for TTTS 2 than AD. However, as SLP is an expensive procedure that uses a large amount of resources, it is unclear whether the SLP procedure is cost-effective. Before a more widespread use of SLP in the treatment of TTTS, it is important to compare the relative cost of the technology to the purported effectiveness. Our objective is to compare the cost-effectiveness of SLP with AD in the treatment of TTTS.
Materials and methods
Using decision-analytic modeling, we compared the costeffectiveness of using no treatment, SLP or AD for the treatment of TTTS. The theoretical target population was all patients presenting with TTTS. The model considered all cases of TTTS, irrespective of Quintero's staging, which grades twin gestations with TTTS according to the severity of cardiovascular complications. 3 The simplified version of the model used to compare the cost-effectiveness of no treatment, SLP and AD is submitted as a Supplementary Figure 1 . The baseline probability for each outcome and the effectiveness for each treatment modality were derived from a systematic review of the English literature and supplemented by a bibliographic review (Table 1 ). In addition to the baseline probabilities, the ranges of reasonable probabilities for the variables were also derived from the literature and used in the sensitivity analysis. When limited literature sources were available, the 95% confidence interval (CI) of the baseline probability for the outcomes was calculated and used for the sensitivity analyses. Overall survival rate was defined as the survival of both twins to the age of 6 months. 2 Cerebral palsy (CP) was assumed to be severe. The analysis was carried out from a societal perspective using a theoretical cohort of 1000 women with TTTS. Using the model, we calculated the overall survival rate and the frequency of CP among survivors after each treatment modality for TTTS. The primary outcome measure was the cost per quality-adjusted life years (QALYs) gained from treating TTTS. 14 Costs incorporated into the model included the costs of procedures and of complications associated with TTTS, as well as of resources used for raising a child with CP (Table 2 ). These costs were primarily derived from published data. Published costs were not available for SLP. For this procedure, we used an average of local charges from two centers (University of California, San Francisco and Universitè Versailles, Poissy, France). These charges were multiplied by a cost-to-charge ratio of 0.6 as an approximation of actual costs. 18 For cases needing a repeat SLP procedure (baseline probability of 0.10, see Table 1 ), the cost of laser was doubled. The cost of AD was based on the requirement of three separate AD procedures, but we varied the number of AD procedures from 1 to 6 in the sensitivity analyses. In the model, all costs were direct medical costs that were adjusted for inflation as necessary to 2006 US dollars. All included costs were discounted at a rate of 3%. 24 The utilities incorporated included those related to intact survival after treatment of TTTS, spontaneous miscarriage <24 weeks, perinatal death and CP. The sources for the utility values Abbreviations: CI, confidence interval; CP, cerebral palsy. Cost-effectiveness of laser versus amniodrainage AO Odibo et al are shown in Table 2 . These were converted to QALYs using the average life expectancy values for the USA and discounted at a 3% rate. We assumed that the life expectancy of infants with CP was reduced by a factor of 0.5 compared with non-CP infants, but varied this to as high as an equal life expectancy in our sensitivity analysis. A cost-utility analysis was carried out and the results were reported as average cost-effectiveness ratios and incremental cost-effectiveness ratios. The incremental cost-effectiveness ratio is the additional cost expended to gain one additional qualityadjusted year in moving from one treatment strategy to another. We designated that an option would be considered cost-effective when its incremental cost-effectiveness ratio was <$50 000 per QALY.
To address the uncertainty regarding several of our baseline assumptions, we carried out one-way, multiway and probabilistic (Monte Carlo simulations) sensitivity analyses commensurate with the degree of uncertainty for the point estimates. The ranges of values used for the sensitivity analyses are shown in Tables 1 and  2 . The Monte Carlo simulation was carried out varying all baseline variables simultaneously for the theoretical cohort of 1000 women with TTTS. A normal distribution was used for the Monte Carlo simulation. All computations were performed using a commercially available decision-analysis software package (TreeAge Pro 2005, Tree Age Inc, Williamstown, MA, USA) and statistical software (STATA SE 9.0, STATA Corp, College Station, TX, USA). The study was exempt from Institutional Review Board approval as it did not involve any patient data.
Results
Under the baseline assumptions, the model favors the use of SLP as the most cost-effective strategy. The cost-effectiveness and incremental cost-effectivess ratios for no therapy, AD and SLP are shown in Table 3 . SLP was cost-effective compared with no treatment at all, and SLP dominated AD, as it was both less expensive and more effective than the AD strategy. The use of SLP cost $1462 per QALY gained by treating TTTS. Using the theoretical cohort, SLP will result in an overall improved perinatal survival of 593/1000 (59.3%) compared with 515/1000 (51.5%) for AD. The number of CP cases in the theoretical cohort using SLP (51/593, 8.5%) would be reduced by 29/1000 compared with the AD strategy (80/515, 15.4%) using AD. The options of SLP and AD were more cost-effective than doing nothing.
When all the variables in Tables 2 and 3 were subjected to oneway and multiway sensitivity analyses, the results remained robust with the exception of the probability of survival after AD. When the overall survival from AD is varied to be >62%, AD became the most cost-effective therapy. Above this threshold, the incremental cost for AD is $21 962 per QALY gained. On varying the probability of survival from SLP between 0.56-0.62, SLP continued to dominate AD, with the cost per QALY gained ranging from $1449 to $1477. At the lowest probability of CP after AD (0.047), SLP remained more cost-effective at an incremental cost of $11 685 per QALY.
On varying the cost of laser therapy to $24 000, SLP continued to dominate AD with an incremental cost of $1867 per QALY. To determine whether the results are driven by the cost of caring for an infant with CP, we evaluated the effect of lowering the the cost of CP to as low as $200 000 (Figure 1 ). SLP remained more costeffective with an incremental cost of $946 per QALY compared with AD. The results of other one-way and two-way sensitivity analyses were not sensitive to varying other costs included in the model.
The Monte Carlo simulation, in which all variables in the tree were varied simultaneously, shows that AD is dominated by SLP in 99.9% of the cases for the theoretical cohort of 1000 women with TTTS.
Discussion
The analysis shows that, on the basis of the data available currently, SLP seems more cost-effective than either no treatment Cost-effectiveness of laser versus amniodrainage AO Odibo et al or AD. Using the commonly accepted threshold of $50 000 per QALY gained in economic analyses, SLP is extremely cost-effective. The option of AD is also cost-effective compared with no treatment using this threshold. However, when SLP is compared with AD, the outcomes are better and the costs are lower leading to a dominant strategy. In this analysis, we did not calculate the cost per perinatal death or CP avoided from treating TTTS as there are no a priori established thresholds of effectiveness for these outcomes.
The model was sensitive only to the probability of survival after AD with a threshold of 62%, above which AD is more cost-effective. This threshold is the highest overall survival rate that has been reported after SLP. As the incremental cost of AD over SLP is only $18 000, it makes sense that if AD garners an increase of about a third of a QALY better than SLP, then it would be incrementally cost-effective. However, as most studies reported so far have an overall survival from AD lower than this threshold value, we believe our results to be robust.
The results of this analysis support efforts at opening more regional centers of excellence for the performance of SLP for the treatment of TTTS. The assumption, however, is that the experts in such centers should be well trained in the technique of SLP to a level similar to those who have conducted the studies cited in this analysis from the literature. The importance of training in the technique of SLP under experienced mentors cannot be overemphasized before establishing a new center for these invasive fetal therapeutic modalities. Similar to many new therapeutic modalities, a steep learning curve is also expected in acquiring the skills to carry out SLP safely.The learning curve not only involves an ability to carry out the SLP procedure, but also includes proficiency in using ultrasound to guide the procedure. There is currently no established guideline for opening new laser units, but it is assumed that new operators have been exposed to a number of procedures. This analysis does not include other costs such as those of establishing a laser treatment unit and the additional manpower needed to operate such a center, because these are highly variable depending on what infrastructures were already in place before starting the program. For example, centers that already use NdYag or diode laser for other procedures may incur less cost in opening new units compared with those starting without any existing laser programs.
The issue of a sequential approach to treating early stages of TTTS remains controversial. 25 This approach entails AD in early stages of TTTS and referral of cases failing AD for SLP. Some disadvantages of carrying out an initial AD include the development of chorion-amnion separation and intra-amniotic bleeding, which precludes treatment by SLP when AD fails. The available evidence does not seem to support AD as a more effective option than SLP at any stage of TTTS. Until more evidence is available, SLP may be the first-line treatment for TTTS whenever this is possible. It is also now becoming more commonly accepted that when advanced stages of TTTS 3, especially in the presence of echocardiographic evidence of cardiac and hemodynamic decompensation in the recipient or donor, are encountered, primary referral for SLP should be considered. The findings of this cost-effectiveness analysis support this practice.
This study has several limitations, including the fact that we did not consider other treatment modalities such as microseptostomy, fetoscopic cord coagulation or medical therapy using non-steroidal anti-inflammatory agents, including indomethacin. We focused on the two most commonly used therapeutic measures for TTS as there is a stronger literature supporting these modalities. In our analysis, we have limited the complications from SLP to spontaneous miscarriage and perinatal death. There are however, other minor complications such as maternal discomfort, need for analgesia and potential infectious morbidities that could not be captured by the model as the literature is silent on the incidence of these complications.
Although the analysis focused on CP, there are only a few studies evaluating other long-term neurodevelopmental outcomes such as severe mental impairment and delayed psychomotor development. These complications, including white matter damage, are known to have a higher background incidence in twin gestations, especially when they are monochorionic. A recent study suggests that the overall incidence of such complications may be as high as 17%. 26 This study calls for more long-term follow-up studies of survivors of TTTS, irrespective of the intervention.
Despite the analysis being carried out from a societal perspective, certain costs such as the loss of earning potential because of fetal loss and the cost of discomfort to primary caregivers were not included in this analysis. Many centers carrying out SLP deliver the patients by the cesarean route on the basis of the perceived risk of uterine rupture. This, therefore, predisposes the woman to further cesarean deliveries in future pregnancy with the associated potential complications. The analysis did not include the future cost of complications from cesarean deliveries as the practice is not evidence-based and as we could not estimate what proportion of the AD would also need a cesarean delivery.
Most of the costs used for the analysis are based on US reimbursement rates. However, for the SLP, we depended on local sources, including one of the centers of excellence for the procedure in France. The cost of the procedure in France is in the lower spectrum of the range provided in Table 2 . This is because the French national health system bears the cost of procedures. Countries with similar health systems as France may therefore find that SLP is even more cost-effective in their systems.
In conclusion, over a wide range of assumptions, our model found SLP to be the most cost-effective therapy for TTTS. The incremental cost-effectiveness ratio of only $1463 per QALY is favorable relative to many other medical and surgical therapies, and thus should be considered a reasonable approach to the treatment of TTTS, both medically and economically. The results of our findings could be useful for decisions regarding third-party coverage for TTTS treatment and support the concept of establishing more regional SLP referral centers.
